

OSOBNJE INFORMACIJE

Marko Skelin

ZVANJE

magistar farmacije

TITULA

doc.dr.sc.

RADNO ISKUSTVO

03.2015 -

Specijalist kliničke farmacije

OB Šibenik

03.2015 -

Specijalist kliničke farmacije

OB Šibenik

12.2011 - 03.2015

Specijalizant kliničke farmacije

OB Šibenik

02.2011 - 12.2011

Magistar farmacije

Gradske ljekarne Šibenik

02.2010 - 06.2011

Profesor Farmaceutske tehnologije u Medicinskoj i kemijskoj školi u Šibeniku

Medicinska i kemijska škola u Šibeniku

02.2010 - 02.2011

Pripravnik u Gradskim ljekarnama Šibenik

Gradske ljekarne Šibenik

OBRAZOVANJE I
OSPOSOBLJAVANJE

02.2019 -

dr.sc

FBF

03.2013 -

poslijediplomski doktorski studij - farmaceutske znanosti

Farmaceutsko-biokemijski fakultet u Zagrebu

10.2004 - 09.2009

magistar farmacije

Farmaceutsko-biokemijski fakultet u Zagrebu

OSOBNJE VJEŠTINE

Materinski jezik Hrvatski

Ostali jezici	RAZUMIJEVANJE		GOVOR		PISANJE
	Slušanje	Čitanje	Govorna interakcija	Govorna produkcija	
engleski	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik

Organizacijske / član organizacijskih odbora nekoliko domaćih kongresa
rukovoditeljske vještine

Poslovne vještine

Vozačka dozvola B kategorija

DODATNE INFORMACIJE

Izdanja

1. Javor E, Allouch A, Osvaldić Galic J, Skelin M. The economic impact of a clinical pharmacist's involvement in the hospital medicines policy in a rural area. *Int J Clin Pract*. Published online September 20, 2021.
2. Javor E, Skelin M, Lucijanic M. Aspirin dosing in cardiovascular disease. *N Engl J Med*. 2021;385(8):764-765.
3. Javor E, Lucijanic M, Skelin M. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;385(1):e4.
4. Lucijanic M, Javor E, Skelin M. Colchicine in patients with chronic coronary disease. *N Engl J Med*. 2021;384(8):776-779.
5. Suton P, Skelin M, Luksic I. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research. *Eur Arch Otorhinolaryngol*. 2021;278(11):4599-4603.
6. Javor E, Lucijanic M, Skelin M. Dietary supplement use and patient outcomes in high-risk early-stage breast cancer. *J Clin Oncol*. 2020;38(18):2110.
7. Lucijanic M, Skelin M, Jurin I, Hadzibegovic I. On interactions between body mass index, type of anticoagulation and outcomes. *Int J Cardiol*. 2020;312:107.
8. Lucijanic M, Lovrinov M, Skelin M. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. *Ann Intern Med*. 2020;173(7):595.
9. Skelin M, Javor E, Lucijanic M. Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer. *JAMA Oncol*. 2020
10. Skelin M, Rahelić D, Skelin P, Lucijanic M. Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. *Diabetes Care* 2019;42:1912-1920. *Diabetes Care*. 2020;43(2):e28-e29.
11. Skelin M, Lucijanic M, Lucijanic J. Dyslipidaemia, a factor worthy of adjustment. *Eur J Heart Fail*. 2019;
12. Javor E, Skelin M, Lucijanic M. Liraglutide in Children and Teens with Type 2 Diabetes. *N Engl J Med*. 2019;381(18):1786-1787.
13. Lucijanic M, Jurin I, Jurin H, Lucijanic T, Starcevic B, Skelin M, Glasnovic A, Catic J, Jurusic A, Hadzibegovic I. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. *International journal of Cardiology*. 2019. [Epub ahead of print]
14. Skelin M, Lucijanic M. Longer Survival with Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association. *JAMA, Oncol*. 2019, [Epub ahead of print]
15. Lucijanic M, Skelin M, Skelin P. Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation. *JAMA*, 2019, 32, 1105.
16. Lucijanic M, Skelin M, Kusec R. Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. *Leukemia*, 2019, [Epub ahead of print]
17. Skelin M, Lucijanic M, Javor E. The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes, *European Heart Journal*, 2019, ehz242.
18. Suton, P, Skelin, M, Rakusic, Z Lukšić I. In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE *Eur Arch Otorhinolaryngol*, 2019, 276, 2113.
19. Suton P, Skelin M, Rakusic Z, Dokuzovic S, Luksic I. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated metaanalysis including trials RTOG 1016 and De-ESCALaTE. *Eur Arch Otorhinolaryngol*, 2019, 276, 1275-1281.
20. Lucijanic M, Skelin M. Platelet Counts and Risk of Major Bleeding With Ibrutinib. *Clin Lymphoma Myeloma Leuk*, 2019, 19, e399.
21. Skelin M, Javor E, Lucijanic M. Aspirin Use and the Risk of Cancer. *JAMA Oncol*, 2019, 5, 912-913.
22. Krnić M, Marolt I, Skelin M, Grulović N, Rahelić D. An observational, multicentre study on different insulin glargine U100 titration algorithms used in patients with type 2 diabetes in daily medical practice in Adriatic countries: The ADRESA study. *Diabetes Res Clin Pract*, 2019, 150, 144-149.
23. Skelin M, Lucijanic M, Miketic T. Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?. *J Clin Oncol*, 2019, JCO1901048.
24. Skelin M, Javor E, Lucijanic M, Lucijanic T, Jakupović L, Rahelić D. The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. *Int J Clin Pract*, 2018, 72, e13274.
25. Skelin M, Lucijanic T, Liberati-Čizmek AM, Klobučar SM, Lucijanic M, Jakupović L, Bakula M, Lončar JV, Marušić S, Matić T, Romić Ž, Dumić J, Rahelić D. Effect of

- timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study. *Endocrine*, 2018, 62, 432-439.
26. Skelin M, Lucijanic M, Javor E. Risk stratification according to insulin type. *Eur J Heart Fail* 2018, 20, 1497.
27. Lucijanic M, Cicic D, Stoos-Veic T, Pejisa V, Lucijanic J, Fazlic Dzankic A, Vlasac Glasnovic J, Soric E, Skelin M, Kusec R. Elevated Neutrophil-to-Lymphocyte-ratio and Platelet-to-Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself? *Anticancer Res*, 2018, 38, 3157-3163.
28. Lucijanic M, Veletic I, Rahelic D, Pejisa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. *Wien Klin Wochenschr*, 2018, 130, 126-133.
29. Rahelić D, Javor E, Lucijanić T, Skelin M. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. *Ann Med*, 2017, 49, 51-62.
30. Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. *Clin Ther*, 2017, 39, 378-403.
31. Lucijanic M, Skelin M, Lucijanic T. Survival analysis, more than meets the eye. *Biochem Med (Zagreb)*, 2017, 27, 14-18.

Konferencije

Predavanja na brojnim domaćim i međunarodnim kongresima

Članstva

European society of oncology pharmacy (ESOP) Hrvatski predstavnik
Povjerenstvo za palijativnu skrb, Hrvatska ljekarnička komora
Izvršni odbor sekcije za onkološku farmaciju,
HFD
Izvršni odbor sekcije za kliničku farmaciju, HFD
Hrvatsko društvo za diabetes i bolesti metabolizma, HLZ član
Endocrine Oncology and Metabolism, scientific journal
Editorial Board
Europska agencija za lijekove vanjski suradnik